Early recognition of whether a product has potential as a new therapy for treating multiple sclerosis (MS) relies upon the quality of the animal models used in the preclinical trials. The promising effects of new treatments in rodent models of experimental autoimmune encephalomyelitis (EAE) have rarely been reproduced in patients suffering from MS. EAE in outbred marmoset monkeys, Callithrix jacchus, is a valid new model, and might provide an experimental link between EAE in rodent models and human MS. Using magnetic resonance imaging techniques similar to those used in patients suffering from MS pathological abnormalities in the brain, white matter of the animal can be visualized and quantified. Moreover, NMR spectroscopy, in combination w...
Magnetic resonance imaging (MRI) is the most important paraclinical tool for assessing drug response...
The potential use of quantitative MRI to characterize early, as well as late, immune-mediated lesion...
The attrition rate of new drugs for central nervous system diseases including multiple sclerosis (MS...
Experimental autoimmune encephalomyelitis in the common marmoset, a nonhuman primate species (Callit...
Experimental autoimmune encephalomyelitis in the common marmoset, a nonhuman primate species (Callit...
Experimental autoimmune encephalomyelitis in the common marmoset, a nonhuman primate species (Callit...
Experimental autoimmune encephalomyelitis in the common marmoset, a nonhuman primate species (Callit...
Experimental autoimmune encephalomyelitis in the common marmoset, a nonhuman primate species (Callit...
Experimental autoimmune encephalomyelitis in the common marmoset, a nonhuman primate species (Callit...
Due to their genetic and immunological proximity to humans, the common marmoset, Callithrix jacchus,...
Multiple sclerosis (MS) is one of the most intensively studied immune-based inflammatory diseases (I...
Magnetic resonance imaging (MRI) is an invaluable tool for the diagnosis and monitoring of patients ...
textabstractMultiple sclerosis (MS) is a major cause of disability in young adults affecting approxi...
Introduction: The translation of scientific discoveries made in animal models into effective treatme...
Despite years of intensive research into multiple sclerosis (MS) scientists have not yet succeeded i...
Magnetic resonance imaging (MRI) is the most important paraclinical tool for assessing drug response...
The potential use of quantitative MRI to characterize early, as well as late, immune-mediated lesion...
The attrition rate of new drugs for central nervous system diseases including multiple sclerosis (MS...
Experimental autoimmune encephalomyelitis in the common marmoset, a nonhuman primate species (Callit...
Experimental autoimmune encephalomyelitis in the common marmoset, a nonhuman primate species (Callit...
Experimental autoimmune encephalomyelitis in the common marmoset, a nonhuman primate species (Callit...
Experimental autoimmune encephalomyelitis in the common marmoset, a nonhuman primate species (Callit...
Experimental autoimmune encephalomyelitis in the common marmoset, a nonhuman primate species (Callit...
Experimental autoimmune encephalomyelitis in the common marmoset, a nonhuman primate species (Callit...
Due to their genetic and immunological proximity to humans, the common marmoset, Callithrix jacchus,...
Multiple sclerosis (MS) is one of the most intensively studied immune-based inflammatory diseases (I...
Magnetic resonance imaging (MRI) is an invaluable tool for the diagnosis and monitoring of patients ...
textabstractMultiple sclerosis (MS) is a major cause of disability in young adults affecting approxi...
Introduction: The translation of scientific discoveries made in animal models into effective treatme...
Despite years of intensive research into multiple sclerosis (MS) scientists have not yet succeeded i...
Magnetic resonance imaging (MRI) is the most important paraclinical tool for assessing drug response...
The potential use of quantitative MRI to characterize early, as well as late, immune-mediated lesion...
The attrition rate of new drugs for central nervous system diseases including multiple sclerosis (MS...